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Background
Following prolonged exposure to NO, soluble guanylyl
cyclase (sGC) becomes desensitized and fails to respond
to additional NO stimulation. We showed that sGC is
desensitized by S-nitrosylation in vitro, in primary smooth
muscle cells (SMC) and in tissues and identified two
cysteines (Cys) targeted by this post-translational modifi-
cation that are involved in sGC desensitization [1]. We
recently discovered that nitroglycerin (GTN) induces S-
nitrosylation of sGC. We also showed that chronic treat-
ment with GTN or acute treatment with S-nitroso-cysteine
(CSNO), which lead to impaired relaxation in vivo, were
accompanied by decreased GTN- or NO-stimulated cGMP
production and characterized by strong S-nitrosylation of
sGC. These observations suggested that desensitization of
sGC by S-nitrosylation could be a mechanism of tolerance
[2]. Based on observations by others that chronic GTN
treatment increases ROS species and that oxidants expo-
sure of cells impaired sGC response to NO, we hypothe-
size that desensitization of sGC by redox-dependent
modification of its Cys is a mechanism underlying the loss
of vascular reactivity in some oxidative vascular diseases.
Results and discussion
We have now identified two additional Cys by Mass Spec
that are, at least in vitro, S-nitrosylated. Mutational analy-
sis of these Cys-sGC mutants seems to indicate that these
four Cys are differentially modified upon exposure to oxi-
dative or nitrosative stress. For example, β1C122 located
in the heme-binding domain appears to be both S-
nitrosylated and oxidized by CSNO and aldosterone treat-
ment, respectively [3]. Comparison of the kinetics and
spectral properties of the purified β1C122A mutant with
the WT indicated that S-nitrosylation of C122 does not
affect the EC50 for NO but reduces the maximal velocity at
saturating concentration of NO. Biochemical studies of
purified sGC exposed to oxidants (H2O2, diamide) under
non-reducing conditions confirmed that some of the Cys
are engaged in disulfide bond and/or modified by glutath-
ionylation, which correlate with decreased sGC activity.
We are now in the process to integrate these in vitro find-
ings in various physiologic and pathophysiologic models
to determine the mechanisms of loss of vascular reactivity
in development of NO resistance, in addition to heme
oxidation [4].
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